Neurocrine Biosciences saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 67 to 74.
IBD's proprietary rating identifies market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the trailing 52 weeks stacks up against all the other stocks in our database.
Decades of market research shows that the best stocks tend to have an RS Rating of above 80 in the early stages of their moves. See if Neurocrine Biosciences can continue to show renewed price strength and clear that threshold.
Can You Really Time The Stock Market?
Neurocrine Biosciences is trying to complete a cup without handle with a 157.98 entry. See if the stock can clear the breakout price in heavy volume.
The company reported 18% earnings growth last quarter. Sales increased 25%.
Neurocrine Biosciences earns the No. 3 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals is the No. 1-ranked stock within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Technical Action?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
